GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Endocrinology

Background:

• Current clinical trials for GLP1-RAs often focus narrowly on atherosclerotic cardiovascular disease (ASCVD) endpoints like major adverse cardiovascular events (MACE).
• This limited scope may overlook the multifaceted benefits of GLP1-RAs across various comorbidities.
• A comprehensive assessment is needed to fully understand the value of these agents.

Purpose of the Study:

• To propose a framework for expanding outcome analyses in large clinical trials of GLP1-RAs.
• To facilitate a more holistic understanding of GLP1-RA benefits across the cardio-kidney-metabolic (CKM) spectrum.
• To inform patient care, clinical guidelines, and insurance coverage decisions.

Main Methods:

• The study outlines a conceptual framework for outcome assessment in clinical trials.
• It advocates for the inclusion of a broader range of endpoints beyond traditional MACE.
• The framework emphasizes multi-comorbidity evaluations within the CKM spectrum.

Main Results:

• The proposed framework allows for a more comprehensive evaluation of GLP1-RA efficacy.
• It moves beyond single-endpoint assessments to a multi-systemic view.
• This approach is expected to reveal wider benefits of GLP1-RAs.

Conclusions:

• A broader outcome assessment framework is crucial for understanding the full value of GLP1-RAs.
• This holistic approach across the CKM spectrum will enhance clinical decision-making.
• The framework supports evidence-based guidelines and insurance coverage for GLP1-RAs.